The Center for Biosimilars recaps the top 5 biosimilars articles for the week of February 5, 2018.
Transcript:
Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of February 5.
Number 5: According to a new review of the literature, managed care professionals can help providers to personalize treatment for patients with macular degeneration, and can encourage adherence.
Number 4: A recent cross-sectional study found that the uptake of biosimilars in the United Kingdom has been highly variable and generally lower than expected.
Number 3: Sales of MabThera dropped sharply due to competition from biosimilars in the European Union.
Number 2: YL Biologics has reported positive phase 3 clinical trial results for its proposed biosimilar referencing Erelzi.
Number 1: The American College of Rheumatology has released a new white paper that supports the use of biosimilars in clinical practice.
Also this week, Dr Robert Levin, a practicing rheumatologist and patient advocate, wrote in The Center for Biosimilars® that, if HHS wants to confront the problem of high drug prices, it must address the growing role of pharmacy benefit managers.
Finally, last week, our e-newsletter asked whether physicians’ expectations of clinical trials are hindering biosimilar acceptance.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.